Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians.
| Autoři: | Xu LL; Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA., Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, Su L, Christiani DC |
|---|---|
| Zdroj: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2002 Dec; Vol. 11 (12), pp. 1555-9. |
| Způsob vydávání: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Comment |
| Jazyk: | English |
| Informace o časopise: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9200608 Publication Model: Print Cited Medium: Print ISSN: 1055-9965 (Print) Linking ISSN: 10559965 NLM ISO Abbreviation: Cancer Epidemiol Biomarkers Prev Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Philadelphia, PA : American Association for Cancer Research, c1991- |
| Výrazy ze slovníku MeSH: | Genetic Predisposition to Disease* , Point Mutation* , Polymorphism, Genetic*, Lung Neoplasms/*epidemiology , Lung Neoplasms/*genetics , Peroxidase/*genetics , Smoking/*adverse effects , White People/*genetics, Adult ; Aged ; Alleles ; Case-Control Studies ; Cohort Studies ; Confidence Intervals ; Disease Susceptibility ; Female ; Genotype ; Humans ; Incidence ; Logistic Models ; Male ; Middle Aged ; Polymerase Chain Reaction ; Polymorphism, Restriction Fragment Length ; Probability ; Prognosis ; Promoter Regions, Genetic ; RNA, Messenger/analysis ; Reference Values ; Risk Factors ; Survival Rate |
| Abstrakt: | The myeloperoxidase (MPO) G-to-A substitution polymorphism in the promoter region of the MPO gene has been associated with a 40-70% reduction in lung cancer risk in several studies, although a recent nested case-control study disputes these findings. MPO is involved in the activation of a number of procarcinogens, including benzo(a)pyrene. The variant A allele has been shown to reduce MPO mRNA expression, thus potentially decreasing carcinogen activation. To confirm results from smaller studies, we evaluated this MPO polymorphism in 988 incident Caucasian lung cancer cases and 1128 controls. Logistic regression evaluated the association between MPO genotype and lung cancer risk, adjusting for age, gender, smoking status, time since quitting smoking, and pack-years of smoking. In the controls, the A allele frequency was 21%, and genotype distribution was in the Hardy-Weinberg equilibrium. Compared with the wild-type G/G genotype, the adjusted odds ratios for the A/A and A/G genotypes were 1.15 (95% confidence interval 0.7-1.9, P > 0.2) and 1.03 (95% confidence interval 0.8-1.3, P > 0.20), respectively. A similar lack of association was seen in analyses stratified by smoking status, median age, a number of smoking variables, disease stage, tumor grade, and histological subtype. These findings are in contrast with earlier studies suggesting a protective effect of carrying the variant A allele. |
| Komentáře: | Comment in: Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1544-9. (PMID: 12496041) Comment on: Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1550-4. (PMID: 12496042) Comment in: Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):683. (PMID: 12869414) |
| Grant Information: | CA74386 United States CA NCI NIH HHS; ES T3207069 United States ES NIEHS NIH HHS; ES/CA06409 United States ES NIEHS NIH HHS; ES00002 United States ES NIEHS NIH HHS |
| Substance Nomenclature: | 0 (RNA, Messenger) EC 1.11.1.7 (Peroxidase) |
| Entry Date(s): | Date Created: 20021224 Date Completed: 20030404 Latest Revision: 20221207 |
| Update Code: | 20240829 |
| PMID: | 12496043 |
| Autor: | Xu LL; Occupational Health Program, Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA., Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, Su L, Christiani DC |
| Jazyk: | angličtina |
| Zdroj: | Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2002 Dec; Vol. 11 (12), pp. 1555-9. |
| Abstrakt: | The myeloperoxidase (MPO) G-to-A substitution polymorphism in the promoter region of the MPO gene has been associated with a 40-70% reduction in lung cancer risk in several studies, although a recent nested case-control study disputes these findings. MPO is involved in the activation of a number of procarcinogens, including benzo(a)pyrene. The variant A allele has been shown to reduce MPO mRNA expression, thus potentially decreasing carcinogen activation. To confirm results from smaller studies, we evaluated this MPO polymorphism in 988 incident Caucasian lung cancer cases and 1128 controls. Logistic regression evaluated the association between MPO genotype and lung cancer risk, adjusting for age, gender, smoking status, time since quitting smoking, and pack-years of smoking. In the controls, the A allele frequency was 21%, and genotype distribution was in the Hardy-Weinberg equilibrium. Compared with the wild-type G/G genotype, the adjusted odds ratios for the A/A and A/G genotypes were 1.15 (95% confidence interval 0.7-1.9, P > 0.2) and 1.03 (95% confidence interval 0.8-1.3, P > 0.20), respectively. A similar lack of association was seen in analyses stratified by smoking status, median age, a number of smoking variables, disease stage, tumor grade, and histological subtype. These findings are in contrast with earlier studies suggesting a protective effect of carrying the variant A allele. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|